Navigation Links
Cephalon Presentation Slides for the 26th Annual JPMorgan Healthcare Conference Now Available
Date:1/7/2008

FRAZER, Pa., Jan. 7 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) announced today that the presentation slides that will be used by the company at the JPMorgan Healthcare Conference are now available on the "Investor Information" section of the company's website at http://www.cephalon.com. On Tuesday, January 8, 2008, Frank Baldino, Jr., Ph.D., Chairman and CEO, will deliver a one hour presentation at the Conference beginning at 2:00 p.m. Pacific Time (5 p.m. Eastern Time).

Live Web Cast and Archived Replay

Members of the financial and investment community, the media and other interested parties can access a live web cast of the presentation through the Investor Information section of the company's website http://www.cephalon.com. Following the live presentation, a replay of the presentation will be available for two weeks on the Company's website.

About Cephalon, Inc.

Cephalon, Inc. is an international biopharmaceutical company dedicated to the discovery, development and commercialization of innovative products in four core therapeutic areas: central nervous system, pain, oncology and addiction. A member of the Fortune 1000, Cephalon currently employs approximately 3,000 people in the United States and Europe. U.S. sites include the company's headquarters in Frazer, Pennsylvania, and offices, laboratories or manufacturing facilities in West Chester, Pennsylvania, Salt Lake City, Utah, and suburban Minneapolis, Minnesota. Cephalon's European headquarters are located in Maisons-Alfort, France.

The company's proprietary products in the United States include: PROVIGIL(R) (modafinil) Tablets [C-IV], FENTORA(R) (fentanyl buccal tablet) [C-II], TRISENOX, AMRIX(R) (cyclobenzaprine hydrochloride extended-release capsules), VIVITROL(R) (naltrexone for extended-release injectable suspension), GABITRIL(R) (tiagabine hydrochloride), NUVIGIL(TM) (armodafinil) Tablets [C-IV] and ACTIQ(R) (oral transmucosal fentanyl citrate) [C-II]. The company also markets numerous products internationally. Full prescribing information on its U.S. products is available at http://www.cephalon.com or by calling 1-800-896-5855.


'/>"/>
SOURCE Cephalon, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkins Lymphoma
2. Cephalon Submits Supplemental New Drug Application for FENTORA
3. Cephalon Announces Strong Third Quarter Financial Results
4. Cephalon Quarterly Conference Call Invitation
5. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
6. Cephalon Reinforces Important Prescribing and Dosing Information for FENTORA
7. Cephalon, Inc. Announces Agreement to Acquire AMRIX, A Once-Daily Extended-Release Muscle Relaxant
8. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
9. deCODE genetics to Webcast Presentation at JPMorgan Annual Healthcare Conference
10. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at JPMorgan Conference
11. Cambrex Presentation at the JPMorgan Healthcare Conference to be Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/25/2017)... ... February 25, 2017 , ... The ... in an ongoing effort to create meaningful change by increasing communication, partnerships and ... emphasis on consumers and patients’ mental health well-being. , Both organizations are dedicated ...
(Date:2/24/2017)... DIEGO , Feb. 24, 2017  Aethlon Medical, ... following note authored by its Chairman and CEO, ... at the Munich Security Conference last Saturday, Bill ... virus could kill more people than nuclear weapons. Mr. ... U.S. and U.K. intelligence agencies, that scientific terrorists have ...
(Date:2/24/2017)... China Biologic Products, Inc. (NASDAQ: CBPO) ("China Biologic" ... in China, today announced its financial results for the fourth ... Quarter 2016 Financial Highlights Total sales ... RMB terms, or increased by 13.6% in USD terms to ... 2015. Gross profit increased by 13.3% to ...
(Date:2/23/2017)... ... February 23, 2017 , ... BellBrook ... portfolio to include an array of biochemical analyses critical for Lead Discovery. ... their hit-to-lead and SAR programs, including inhibitor potency and selectivity, mechanism of action, ...
Breaking Biology Technology:
(Date:1/31/2017)... Mass. , Jan. 31, 2017  Spero ... novel therapies for the treatment of bacterial infections, ... set of antibacterial candidates from Pro Bono Bio ... increased prevalence of multi-drug resistant forms of Gram-negative ... Cantab Anti Infectives Ltd, a PBB group company. ...
(Date:1/26/2017)... 26, 2017  Acuity Market Intelligence today released ... Digital Identity".  Acuity characterizes 2017 as a "breakout" ... adoption reflects a new understanding of the potential ... and digital identity are often perceived as threats ... , Principal of Acuity Market intelligence. "However, taken ...
(Date:1/24/2017)... 24, 2017  It sounds simple and harmless—an ... monitors vital signs and alerts parents on their ... saturation level drops. But pediatric experts argue that ... with no evidence of medical benefits, especially to ... aggressively to parents of healthy babies, promising peace ...
Breaking Biology News(10 mins):